Safety and Efficacy of Transcatheter Edge-to-Edge Repair for Atrial Functional Mitral Regurgitation

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.

Also called NCT07414225

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07414225
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07414225. Randomized; no masking; primary purpose treatment. Start 2026-06-01 (actual); primary completion 2030-02-25 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Transcatheter Edge-to-Edge Repair for Atrial Functional Mitral Regurgitation
Acronym
STAR
Condition
Atrial Functional Mitral Regurgitation
Intervention (Device)
Transcatheter Edge-to-Edge Repair
Intervention (Drug)
Guideline-Directed Medical Therapy (GDMT) for cardiovascular disease
Lead sponsor
Beijing Anzhen Hospital (class: other)

Record details

Record id
cardio:ct-nct07414225
Content hash
181cef9fd64b9de93633a35be733be8b95ae059cf661f2d656e67ccde0aac80c